Amy Wagers

An HSCI approach to rhabdomyosarcoma

September 29, 2013

Rhabdomyosarcoma is a rare childhood cancer that arises in muscle stem cells. Between 250-350 cases are treated each year. The disease most commonly begins as a noticeable swelling in the arms, legs, head, neck, or groin, and is treated by surgical removal of the tumor, as well as chemotherapy or irradiation. Currently, about 80% of patients diagnosed with rhabdomyosarcoma survive, as the disease is often caught early enough for intervention.

In this feature, one senior investigator, one junior investigator, and one postdoctoral researcher—all working...

Read more about An HSCI approach to rhabdomyosarcoma

Cross-country collaboration leads to new model of leukemia development

July 31, 2013

Eight years ago, two former Stanford University postdoctoral fellows, one of them still in California and the other at the Harvard Stem Cell Institute (HSCI) in Cambridge, began exchanging theories about why patients with leukemia stop producing healthy blood cells. What was it, they asked, that caused bone marrow to stop producing normal blood-producing cells?... Read more about Cross-country collaboration leads to new model of leukemia development